Other substances

NIH-CoVnb-112

An anti-RBD (SARS-CoV-2 Spike) nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

NIH-CoVnb-112 is a nanobody identified via its affinity for SARS-CoV-2 Spike protein RBD using the phage display technique. It originated from a B-cell of a llama immunized with recombinant Spike protein (Esparza et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
Spike protein Biophysical assay In vitro Antibody 		in vitro biophysical assay; hACE2 HEK293 cells 4.00

The nanobody potently binds the SARS-CoV-2 spike protein RBD epitopes in vitro (with KD of 4.94 nM). It also competitively inhibits ACE2 binding (EC50 of 1.11 nM).  It inhibits pseudovirus infection with EC50 of 8.3 nM when nebulized. The nanobody retains its structural integrity when nebulized.

 Dec/22/2020

AI-suggested references

Link Publication date
Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19
Mar/16/2022
Export (.csv)